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S UMMA R Y
BACKGROUND : Tuberculosis (TB) patients receiving
anti-tuberculosis treatment may experience serious
adverse drug reactions (ADRs) such as hepatotoxicity.
Variants of the N-acetyltransferase 2 (NAT2) gene may
increase the risk of experiencing such toxicity events.
OB J E C T I V E : To provide a comprehensive evaluation of
the evidence base for associations between NAT2
variants and anti-tuberculosis drug-related toxicity.
METHOD : This was a systematic review and meta-
analysis. We searched for studies in Medline, PubMed,
EMBASE, BIOSIS and Web of Science. We included data
from 41 articles (39 distinct cohorts of patients). We
pooled effect estimates for each genotype on each
outcome using meta-analyses stratified by country.
R E SU LT S : We assessed the quality of the included
studies, which was variable, with many areas of
concern. Slow/intermediate NAT2 acetylators were
statistically significantly more likely to experience
hepatotoxicity than rapid acetylators (OR 1.59,
95%CI 1.26–2.01). Heterogeneity was not detected
in the overall pooled analysis (I2 ¼ 0%). NAT2
acetylator status was significantly associated with
the likelihood of experiencing anti-tuberculosis drug-
related hepatotoxicity.
CONC LU S I ON : We encountered several challenges in
performing robust syntheses of data from pharmacoge-
netic studies, and we outline recommendations for the
future reporting of pharmacogenetic studies to enable
high-quality systematic reviews and meta-analyses to be
performed.
K E Y WORD S : tuberculosis; pharmacogenetics; adverse
events; evidence synthesis
TUBERCULOSIS (TB) is one of the most important
challenges in global health. There were an estimated
1.3 million TB deaths in 2016 among human
immunodeficiency virus (HIV) negative people and
374 000 deaths among HIV-positive people.1 The
World Health Organization (WHO) recommends a
combination of four first-line drugs for individuals
with drug-susceptible TB: isoniazid (INH), rifampicin
(RMP), ethambutol (EMB) and pyrazinamide
(PZA).1
TB patients receiving a combination of these drugs
may experience adverse drug reactions (ADRs), the
most serious of which is anti-tuberculosis drug-
induced hepatotoxicity (ATDH). Reported incidence
rates of ATDH among patients treated with standard
multidrug treatment vary from 2% to 28%, depend-
ing on the regimen given, definition of ATDH and
patient characteristics such as age, race and sex.2
ATDH can be fatal, with reported mortality rates of
6–12% if drugs are not promptly stopped.3 ATDH
and other anti-tuberculosis drug-related adverse
effects also contribute to non-adherence, eventually
leading to treatment failure, relapse and the emer-
gence of drug resistance.2
The proposed genetic risk factors for ATDH
include polymorphisms of the N-acetyltransferase 2
(NAT2) gene, which codes for the drug-metabolising
enzyme, NAT2.4,5 NAT2 polymorphisms may affect
the activity of the NAT2 enzyme, altering the
chemical modification of anti-tuberculosis drugs
and their metabolites in the liver, leading to hepatic
adverse reactions.6 Toxic metabolites may also cause
other toxicity events, such as peripheral neuropathy
and maculopapular eruption, although the majority
of evidence on the pharmacogenetics of anti-tuber-
culosis drugs focuses on hepatotoxicity.
INH is the anti-tuberculosis drug for which the
genetic contribution to ATDH has been most widely
studied and is best understood. Specifically, it is
thought that NAT2 acetylator status may be associ-
ated with INH-related hepatotoxicity because NAT2
is one of the main enzymes involved in INH
metabolism in the liver. There are three phenotypes
of acetylator status. Individuals who are slow NAT2
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acetylators have higher plasma drug concentrations.
This may be beneficial for treatment efficacy, but may
also cause an accumulation of toxic metabolites as
part of the metabolic activation of acetylhydrazine to
harmless diacetylhydrazine. INH suppresses the
acetylation of acetylhydrazine to produce more toxic
metabolites, which contributes to the increased risk
of hepatitis.7 Fast acetylators have lower plasma drug
concentrations, and so treatment may be less effec-
tive, but also less toxic. Intermediate acetylators fall
between these two extremes.
RMP and PZA have also been reported to be
hepatotoxic;8 however, the mechanisms for RMP-
and PZA-induced hepatotoxicity are not known.9
The OATP1B1*15 haplotype has been reported to be
a predictor of RMP-induced liver injury;10 no
research into the genetic predictors of PZA-induced
hepatotoxicity has been reported.11 No hepatotoxic-
ity has been described for EMB.8
The objective of this systematic review and meta-
analysis was to evaluate evidence on the effect of
NAT2 on anti-tuberculosis drug-related toxicity in
TB patients receiving anti-tuberculosis treatment.
Meta-analyses investigating the effect of NAT2 on
toxicity outcomes have been published,6,12–15 but the
conclusions from these have been conflicting. Our
review and meta-analysis updates and adds to the
evidence base on associations between NAT2 and
anti-tuberculosis drug-related toxicity.
METHODS
This review was conducted in line with the methods
outlined in our protocol (PROSPERO registration
number: CRD42017068448).16 A search strategy
and study selection process enabled identification of
studies that investigated the association between any
genetic variant and anti-tuberculosis drug-related
toxicity. However, in this article, we focus only on
the subset of studies that considered NAT2 variants.
Studies investigating associations between other
genetic variants and anti-tuberculosis drug-related
toxicity will be reported separately.
Selection criteria
Types of studies
We included cohort studies, case-control studies and
randomised controlled trials (RCTs). We did not
include studies on case series because this type of
study design would be inappropriate to investigate
the effect of genetic variants on anti-tuberculosis
drug-related toxicity. We did not require a minimum
number of enrolled patients for a study to be included
in our review.
Types of participants
We included studies that recruited TB patients who
were either already established on anti-tuberculosis
treatment or commencing treatment (at least one of
INH, RMP, PZA or EMB), and who were genotyped
to investigate the effect of genetic variants on anti-
tuberculosis drug-related toxicity. We only included
studies where .50% of included patients were TB
patients receiving anti-tuberculosis treatment.
Types of outcomes
We included studies that measured any drug-related
toxicity outcomes.
Search strategy
An information specialist (EK) designed the search
strategy (Appendix Tables A.1* and A.2), and
searched for relevant studies in Medline, PubMed,
EMBASE, BIOSIS andWeb of Science (date of search:
3 March 2016). We searched reference lists from
relevant studies manually, and contacted experts to
identify eligible studies. We included studies pub-
lished in English only. We did not restrict by year of
publication or publication status.
Study selection
The search results were imported to Covidence.17 We
removed duplicates, and one author (MR) scanned
the study abstracts to remove irrelevant studies. A
second author (AJ, JK or KD) independently screened
a sample of 10% of studies.
We obtained the full text for each potentially
relevant study. One reviewer (MR) assessed eligibility
based on the selection criteria. A second author (AJ,
JK or KD) independently assessed a sample of 10% of
studies for eligibility. Disagreements between the two
reviewers at the abstract and full-text screening stages
were resolved through discussion, and by consulting a
third author if necessary.
Outcomes
The primary outcome of this review was hepatotox-
icity by any definition used by the original investiga-
tors. The secondary outcomes were all other toxicity
outcomes.
Data collection
We designed and piloted a data extraction form. We
collected data on study design, participant charac-
teristics, and treatment regimen and outcomes. One
author (MR) extracted data in accordance with the
methods outlined in the Cochrane Handbook18 and
The HuGENet HuGE Review Handbook.19 A
second author (AJ, JK or KD) independently
extracted all outcome data. Disagreements between
the two reviewers were resolved through discussion,
and by consulting a third author if necessary. We
*The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2018/
00000023/00000003/art000 .....
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contacted study authors if outcome data necessary
for inclusion in a meta-analysis were not published
in the paper.
We contacted individuals who were listed as
authors of multiple included articles to enquire
whether there was overlap between articles in terms
of the patient cohorts. We examined locations, dates
of recruitment and other study characteristics to
identify articles that reported outcomes for the same
patient cohort. If an author confirmed that multiple
articles reported outcomes for the same patient
cohort, or if we suspected this based on reported
study characteristics, we assigned a group identifier
(GI) to these articles, and ensured that no data for the
same patient cohort were included more than once in
any meta-analysis.
Quality assessment
One author applied criteria for the quality assessment
of pharmacogenetic studies20 to each study. A second
author (AJ) independently assessed the quality of a
sample of 10% of studies. Disagreements between the
two reviewers were resolved through discussion. We
obtained the number of studies meeting each criterion
and summarised this information in the text.
Data synthesis
We performed meta-analyses for associations be-
tween NAT2 and any anti-tuberculosis drug-related
toxicity outcome that were investigated by at least
two studies. The effects of both NAT2 acetylator
status (as predicted using genotyping methods) and
individual NAT2 single-nucleotide polymorphisms
(SNPs) were investigated.
Primary analysis
The primary analysis compared risk of hepatotoxicity
for slow/intermediate acetylators in comparison with
rapid acetylators. Data were pooled from studies that
reported data for each acetylator group separately
together with data from studies that combined slow
and intermediate acetylator groups.
Two sensitivity analyses were conducted. The first
was pairwise comparisons of slow vs. rapid acetylator
status, and intermediate vs. rapid acetylator status.
Here, it was only possible to include data from studies
that reported on each acetylator group separately.
The second was comparison of slow vs. rapid/
intermediate acetylator status. Here, data were
pooled from studies that combined data for interme-
diate and rapid acetylator groups, and from studies
that reported data for each acetylator group sepa-
rately.
Secondary analysis
The secondary analysis compared the risk of hepato-
toxicity between genotype groups for NAT2 SNPs.
For each SNP, two pairwise comparisons were
undertaken: heterozygous genotype vs. homozygous
wild-type (wt), and homozygous mutant-type vs.
homozygous wt. For SNPs investigated by one study
only, odds ratios (ORs) comparing genotype groups
were calculated and summarised in a table, together
with the pooled estimates from the meta-analyses.
There were insufficient data to perform meta-
analyses for an association betweenNAT2 (acetylator
status and individual SNPs) and other toxicity
outcomes; ORs and 95% confidence intervals (CIs)
for each pairwise comparison were calculated and
reported in a table.
Meta-analyses were performed using Stata v 14
(metan package) (StataCorp, College Station, TX,
USA);21 ORs with 95%CIs were the chosen measure
of effect. We used the random-effects model because
we anticipated heterogeneity between studies due to
differences in study design, methodological quality,
ethnicity of participants and outcome definitions. The
random-effects model used the method of DerSimo-
nian and Laird,22 with the estimate of heterogeneity
being taken from the Mantel-Haenszel model.23 If
zero events were observed in one of the genotype
groups, a continuity correction of 0.5 was used. Data
were excluded from the analysis if there were no
patients in one of the genotype groups in a
comparison.
The HuGENet HuGE Review Handbook recom-
mends that meta-analyses of genetic association
studies be stratified by ethnicity, and that meta-
analyses should only be performed if effect estimates
for different ethnic groups appear sufficiently simi-
lar.19 However, information on participants’ ethnicity
was sparsely reported in the studies included in our
review. We therefore performed analyses stratified by
the countries in which studies were conducted as a
proxy for ethnicity.
Investigation of heterogeneity
We assessed heterogeneity by visually examining
forest plots, and by referring to the I2 statistic. If
substantial heterogeneity had been observed
(.50%),18 we planned to undertake subgroup
analyses according to study design, outcome defini-
tions, treatment regimens and date of study publica-
tion.
Selective reporting
We assessed the possibility of selective reporting as
part of the quality assessment. Potential sources of
selective reporting considered were genetic variants,
outcomes and modes of inheritance.20
Publication bias
We produced a funnel plot for the primary analysis to
assess the risk of publication bias.
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RESULTS
Included and excluded studies
A Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) flow chart showing
the selection of studies during the literature search is
provided in Figure 1 (for more information, visit
www.prisma-statement.org).24 The initial search
identified 77 articles investigating the association
between any genetic variant and anti-tuberculosis
drug-related toxicity, from which 52 distinct cohorts
of patients were identified (Figure 1).
Forty-six articles reported data for the association
between NAT2 variants and anti-tuberculosis drug-
related toxicity; from these articles, 40 distinct
patient cohorts were identified. In this review, we
include data from 40 articles (39 distinct patient
cohorts).25–64 We did not include data from the
remaining six articles.65–70 Of those six articles, five
reported data for patient cohorts for whom data were
also reported in other articles (or we suspected that
this was the case); for the sixth article,70 the numbers
of patients in each genotype group were not reported,
and we were unable to obtain this information from
the authors. The characteristics of studies included in
this review are provided in Appendix Table A.3.
Quality assessment
Choosing which genes and SNPs to genotype
Twenty-seven articles reported the reasons for choos-
ing all genes and SNPs investigated. For the 13
articles28,31,33,37,48,51,53,57,59,60,62–64 that did not re-
port this information, no articles limited their
reporting to only statistically significant associations.
Therefore, there was no evidence to suggest that
selective reporting of genes and SNPs had occurred.
Sample size
The median sample size was 170 (interquartile range
108.5–285). Only two articles26,63 provided details of
the a priori power to detect pre-specified effect sizes.
Study design
Eleven articles described case-control studies, 27
articles described prospective cohorts, one article
described a retrospective cohort and one article
described an RCT. For one case-control study,33 the
case and control groups were not clearly defined. No
articles describing case-control studies reported that
the two groups were genotyped in mixed batches.
Reliability of genotypes
Only three articles26,32,46 mentioned genotype
quality control procedures, and only 12 arti-
cles26,33,35,37,38,41,45,49–51,53,55 compared the geno-
type frequencies of all investigated SNPs to those
previously published for the same population. Of
the articles describing case-control studies and
retrospective cohorts, only two45,46 mentioned that
genotyping personnel were blinded to outcome
status.
Missing genotype data
For most articles (29/40), on comparison of the
number of participants included in the analyses with
the study sample size, it was apparent there were no
missing genotype data. For the remaining 11
articles,32,33,42–44,53,56,58,60,63,64 only five arti-
cles32,56,58,63,64 summarised the extent of missing
data for all the genes and SNPs analysed. None of
these articles described checking whether missing
data were randomly distributed.
Population stratification
One article mentioned undertaking tests for popula-
tion stratification;53 no population stratification was
identified. One article used a study design that
ensured that the included patients were from a non-
diverse ethnic group.48 All other studies were at




reported testing for Hardy-Weinberg equilibrium
(HWE) for all investigated SNPs, and a further
three25,51,56 tested for HWE for a subset of SNPs.
The remaining 14 articles reported no testing for
HWE.
Figure 1 Flow chart of study according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA).24 NAT2¼ N-acetyltransferase 2.
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Mode of inheritance
Nineteen articles made a specific assumption re-
garding the under ly ing mode of inher i -
tance.25,29,31,34,35,40,43,44,48,50,53,55–57,59–61,63,64 Of
these, only two provided justification;29,60 for the
remaining 17 articles, there was a risk of selective
reporting under different modes of inheritance. Two
articles42,58 applied models assuming different modes
of inheritance to the genotype data, although only
one of these articles42 adjusted these analyses for
multiplicity of testing.
Choice and definition of outcomes
There was large variation in the definition of
hepatotoxicity (Appendix Table A.4). Of the 37
articles reporting hepatotoxicity data, one did not
provide a definition,62 one provided a vague defini-
tion,30 and the remaining 35 articles provided 31
different definitions. Definitions of other toxicity
outcomes were generally not sufficiently detailed
(Appendix Table A.5).
Nine articles did not provide justification for the
choice of outcomes, but outcomes were in line with
the main study aim as conveyed in the Introduction
section of the article.27,32,38,49,50,52,56,57,63 The re-
maining articles all provided justification for the
choice of outcomes. There was therefore no evidence
to suggest that selective reporting of outcomes had
occurred.
Treatment adherence
Six articles31,32,43,45,50,57 mentioned assessing treat-
ment adherence. One article48 reported that treat-
ment was administered under DOTS; it was therefore
not necessary to measure adherence. Of the six
articles that reported assessing adherence, one did
not report adjusting the analyses for adherence.50 It
was not necessary to adjust for adherence in the
analyses of two articles because patients were
reported to have good treatment adherence.31,32
Association between NAT2 variants and anti-
tuberculosis drug-related toxicity
NAT2 acetylator status and hepatotoxicity
A forest plot displaying the results of the primary
analysis is given in Figure 2. Slow/intermediate
acetylators were significantly more likely to experi-
ence hepatotoxicity than rapid acetylators (OR 1.59,
95%CI 1.26–2.01). No heterogeneity was detected in
this analysis (I2¼ 0%).
Results of the sensitivity analyses are provided in
Appendix Figures A.1–A.3. Results from the pair-
wise comparisons suggested that slow acetylators
were significantly more likely to experience hepato-
toxicity than rapid acetylators (OR 3.68, 95%CI
2.23–6.09, I2 ¼ 60.0%), but there were no signifi-
cant differences between intermediate and rapid
acetylators (OR 1.12, 95%CI 0.87–1.45, I2 ¼ 0%).
The sensitivity analysis that compared slow acetyla-
tors with rapid/intermediate acetylators suggested
that slow acetylator status significantly increased the
risk of hepatotoxicity (OR 3.12, 95%CI 2.45–3.97,
I2¼ 59.0%).
Moderate heterogeneity was observed in the
sensitivity analyses of slow vs. rapid acetylator status,
and slow vs. rapid/intermediate acetylator status.
Such moderate heterogeneity may have been due to
the variable distribution of genotypes in different
geographic areas.
The funnel plot for the primary analysis (Appendix
Figure A.4) provided no evidence of publication bias.
NAT2 SNPs and hepatotoxicity
The included studies reported data for 12 NAT2
SNPs. A summary of all data for the association
between NAT2 SNPs and hepatotoxicity is provided
in Table 1. There were sufficient data to perform
meta-analyses for six SNPs. Forest plots showing the
results of these meta-analyses are provided in Figure
2. The four main findings from these meta-analyses
are shown below.
1 For 590G-A and 857G-A, both heterozygous
genotype and homozygous mutant-type signifi-
cantly increased hepatotoxicity risk compared
with homozygous wt (590G-A: GA vs. GG, OR
1.30, 95%CI 1.06–1.59, I2¼0%; AA vs. GG, OR
2.05, 95%CI 1.24–3.40, I2¼47.7%; 857G-A: GA
vs. GG, OR 1.30, 95%CI 1.03–1.64, I2 ¼ 0.9%;
AA vs. GG, OR 1.99, 95%CI 1.02–3.91, I2 ¼
11.3%).
2 For 282C-T, homozygous mutant-type significantly
increased hepatotoxicity risk compared with ho-
mozygous wt (OR 3.95, 95%CI 2.21–7.05, I2 ¼
5.5%); however, no significant difference was
observed for heterozygous genotype compared
with homozygous wt (OR 1.27, 95%CI 0.80–
2.02, I2¼ 0%).
3 For 481C-T, heterozygous genotype significantly
increased hepatotoxicity risk compared with ho-
mozygous wt (OR 1.48, 95%CI 1.12–1.97, I2 ¼
0%); however, no significant difference was ob-
served for homozygous mutant-type compared
with homozygous wt (OR 1.91, 95%CI 0.93–
3.92, I2 ¼ 34.1%). The lack of statistical signifi-
cance for the latter comparison may have been
caused by the relatively small number of homozy-
gous mutant-type patients (n ¼ 162) among the
patients contributing data to this analysis (n ¼
3604)
4 For 341T-C and 803A-G, no significant differences
were observed for either pairwise comparison
(341T-C: TC vs. TT, OR 1.15, 95%CI 0.72–1.82,
I2¼0%; CC vs. TT, OR 1.54, 95%CI 0.58–4.04, I2
¼0%; 803A-G: AG vs. AA, OR 1.14, 95%CI 0.67–
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1.96, I2¼0%; GG vs. AA, OR 1.90, 95%CI 0.66–
5.52, I2¼ 0%).
Results were relatively homogeneous between
studies for most comparisons, except for the com-
parison between homozygous mutant-type and ho-
mozygous wt for the 590G-A SNP (I2¼47.7%). This
moderate heterogeneity may have been due to the
variable distribution of genotypes in different geo-
graphic areas (Table 1; Appendix Figure A.5).
NAT2 variants and other toxicity outcomes
A summary of all data for the association between
NAT2 variants and toxicity outcomes (other than
hepatotoxicity) is provided in Table 2. Each reported
result is based on data from a single study because
Figure 2 Slow/intermediate vs. rapid acetylator status for the outcome of hepatotoxicity. * Conducted in LTBI populations.
†Caucasian: 38 (43%), Hispanic: 8 (9%), African: 22 (25%), South American: 15 (17%), Asian: 5 (6%), Middle Eastern: 1 (1%).
‡Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%), Hispanic: 7 (4%), Middle Eastern: 8 (5%), First nations: 5 (3%),
Other/mixed/unknown: 7 (4%). OR¼ odds ratio; CI¼ confidence interval; GI¼ group identifier; LTBI¼ latent tuberculous infection.
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there were no comparisons where more than one
study provided data (Table 2).
For peripheral neuropathy, no significant associa-
tions were reported for either of the pairwise
comparisons conducted for acetylator status, 191G-
A or 341T-C. Similarly, for skin rash and eosinophil-
ia, the pairwise comparisons for acetylator status
demonstrated no significant effects. None of the SNPs
investigated by Kim et al. had a significant effect on
anti-tuberculosis drug-induced maculopapular erup-
tion.43 Slow acetylators were significantly more likely
to experience adverse drug-induced hepatotoxicity
outcomes (definition unclear; OR 3.31, 95%CI 1.03–
10.62), and ADRs (defined as at least one of the
following: gastric, joint, neuromuscular or skin
reactions, hepatotoxicity; OR 3.20, 95%CI 1.31–
7.80) compared with rapid or intermediate acetyla-
tors. However, slow acetylator status was not found
to increase the risk of gastrointestinal ADRs.
DISCUSSION
There is substantial evidence for the association
between NAT2 variants and anti-tuberculosis drug-
related toxicity outcomes, as previously identified
and as our systematic review confirmed. However, we
established that performing robust synthesis of this
evidence is challenging due to the variability between
studies in terms of how participants are classified
according to genotype; choice and definition of
outcomes and variants to investigate; ethnicity of
participants; and methodological quality. In conduct-
ing our review, we carefully considered these chal-
lenges, stratifying meta-analyses by genetic variants,
genotype contrasts and outcomes. We also stratified
further by the country where the study was conducted
as a proxy for ethnicity, which has not been widely
reported. We supplemented our data synthesis with a
rigorous assessment of the methodological quality of
included studies.
Meta-analyses
Where possible, meta-analyses were undertaken to
improve the power to estimate genetic effects. We
found that slow/intermediate acetylators were signif-
icantly more likely to experience hepatotoxicity than
rapid acetylators. This result is consistent with the
findings of several meta-analyses,12–15 but not con-
sistent with the meta-analysis reported by Sun et al.,6
who did not identify a significant association between
slow acetylator status and hepatotoxicity. However,
the search date for Sun et al.6 (May 2007) is several
years earlier than the search dates for the other meta-
analyses, and many relevant studies have been
published in recent years. As more studies are
published, the power to detect a statistically signifi-
cant association increases.
Meta-analyses on individual SNPs of the NAT2
gene have not been published, so our results add to
the existing knowledge of the association between
NAT2 variants and hepatotoxicity.
INH remains an essential drug in the treatment of
active TB and is the mainstay of chemoprophylaxis in
latent tuberculous infection (LTBI), an intervention
that is being rapidly expanded in recent strategies to
eliminate TB as a public health problem. The global
use of INH will therefore greatly increase worldwide
in the coming decade. While transaminase testing is a
readily available biomarker of possible ATDH,
baseline values have modest predictive value and
routine monitoring is not generally recommended.
Where slow acetylator status is common, pharmaco-
genetic testing could make a clinically useful contri-
bution to risk stratification for ATDH. However, the
need for testing of a relatively large panel of SNPs and
the current lack of a clear substitute to INH for LTBI
chemoprophylaxis mean that such a strategy may not
be cost-effective or feasible. Studies investigating the
cost-effectiveness and/or feasibility of such a strategy
would be beneficial. Nevertheless, based on the
nearly three-fold increased risk of ATDH in slow
acetylators observed in this review, pharmacogenetic
epidemiology should certainly be a factor in national
policymaking on the need for transaminase monitor-
ing during treatment of active TB and LTBI locally.
Quality assessment
The quality of included studies varied, with some areas
of concern. Most studies were significantly smaller
than typically required to provide sufficient power,20
and the reader was left unaware of the likelihood of
false-negatives in all studies due to the lack of reported
a priori power calculations. The fact that no studies
described checking that missing data were missing at
random is also a concern; missing genotype data are
unlikely to be missing at random because heterozy-
gotes are notoriously more difficult to call than
homozygotes.20 Few studies reported testing of
HWE, which can highlight genotyping errors, popu-
lation stratification and other problems.20 Further-
more, in studies that did not adjust for treatment
adherence, the proportion of variability explained by
genetic variants may have been underestimated.20
As the quality assessment was qualitative rather
than quantitative, it was not possible to exclude
studies from meta-analyses based on a single sum-
mary score. Although we identified issues of concern
relating to some of the quality criteria, we did not
identify any studies that were thought to be of
particularly poor quality overall, so we did not deem
it necessary to exclude any single study in sensitivity
analyses.
Limitations
Most included studies did not report the ethnic
background of participants. We therefore performed
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190C-T Het (CT) vs. hom
wt (CC)
China (1 study) NR 0.21 (0.01–4.38) 101 107 NA
Hom MT (TT) vs.
hom wt (CC)
China (1 study) NR Data excluded*
191G-A
(rs1801279)
Het (GA) vs. hom
wt (GG)
Taiwan (1 study) NR Data excluded*
Turkey (1 study) NR Data excluded*
All (0 studies) NA NA NA NA
Hom MT (AA) vs.
hom wt (GG)
Taiwan (1 study) NR Data excluded*
Turkey (1 study) NR Data excluded*
All (0 studies) NA NA NA NA
282C-T
(rs1041983)
Het (CT) vs. hom
wt (CC)
China (1 study) NR 1.28 (0.67–2.44) 65 98 NA
Taiwan (1 study) NR 0.50 (0.06–4.06) 70 284 NA
Indonesia (1 study) 100% Indonesian 1.25 (0.51–3.05) 27 148 NA
Brazil (1 study) NR 1.67 (0.56–5.00) 14 216 NA
All (4 studies) 1.27 (0.80, 2.02) 176 746 0.0
Hom MT (TT) vs.
hom wt (CC)
China (1 study) NR 7.00 (2.89–16.98) 60 51 NA
Taiwan (1 study) NR 1.33 (0.05–32.91) 69 277 NA
Indonesia (1 study) 100% Indonesian 3.41 (1.38–8.40) 31 94 NA
Brazil (1 study) NR 2.07 (0.59–7.25) 12 185 NA
All (4 studies) 3.95 (2.21, 7.05) 172 607 5.5
341T-C
(rs1801280)
Het (TC) vs. hom
wt (TT)
China (1 study) NR 1.63 (0.45–5.94) 101 107 NA
Taiwan (2 studies) NR 1.26 (0.58–2.75) 114 376 0.0
Indonesia (1 study) 100% Indonesian 1.13 (0.54–2.35) 49 188 NA
Brazil (1 study) NR 0.66 (0.18–2.42) 10 187 NA
All (5 studies) 1.15 (0.72–1.82) 274 858 0.0
Hom MT (CC) vs.
hom wt (TT)
China (1 study) NR Data excluded*
Taiwan (2 studies) NR 1.18 (0.08–16.93) 105 355 41.4
Indonesia (1 study) 100% Indonesian 1.32 (0.13–13.01) 38 149 NA
Brazil (1 study) NR 1.75 (0.50–6.13) 12 122 NA
All (4 studies) 1.54 (0.58, 4.04) 155 626 0.0
481C-T
(rs1799929)
Het (CT) vs. hom
wt (CC)
China (3 studies) 1 study, 100% Chinese;
2 studies, NR
1.66 (1.11–2.48) 259 2027 0.0
Taiwan (1 study) NR 4.12 (0.25–66.63) 70 285 NA
Indonesia (1 study) 100% Indonesian 1.01 (0.47–2.14) 49 188 NA
India (1 study) NR 1.82 (0.89–3.71) 39 154 NA
Tunisia (1 study) NR 1.33 (0.29–6.06) 8 42 NA
Turkey (1 study) NR 2.17 (0.88–5.36) 28 63 NA
Brazil (1 study) NR 0.44 (0.14–1.37) 14 216 NA
All (9 studies) 1.48 (1.12, 1.97) 467 2975 0.0
Hom MT (TT) vs.
hom wt (CC)
China (3 studies)† 1 study, 100% Chinese;
2 studies, NR
0.81 (0.19–3.41) 41 1155 NA
Taiwan (1 study) NR Data excluded*
Indonesia (1 study) 100% Indonesian 1.28 (0.13–12.66) 39 149 NA
India (1 study) NR 5.38 (1.99–14.49) 27 97 NA
Tunisia (1 study) NR 3.60 (0.83–15.57) 10 34 NA
Turkey (1 study) NR 0.93 (0.17–5.08) 14 46 NA
Brazil (1 study) NR 1.19 (0.34–4.09) 13 132 NA
All (6 studies) 1.91 (0.93, 3.92) 144 1613 34.1
499G-A Het (GA) vs. hom
wt (GG)
China (1 study) NR 0.21 (0.01–4.38) 101 107 NA
Hom MT (AA) vs.
hom wt (GG)
China (1 study) NR Data excluded*
590G-A
(rs1799930)
Het (GA) vs. hom
wt (GG)
China (3 studies) 1 study, 100% Chinese;
2 studies, NR
1.19 (0.86–1.66) 236 1921 15.6
Taiwan (2 studies) NR 1.16 (0.74–1.82) 104 356 0.0
South Korea (1 study) NR 1.99 (1.06–3.74) 57 145 NA
Indonesia (1 study) 100% Indonesian 1.17 (0.58–2.36) 38 173 NA
India (1 study) NR 1.38 (0.70–2.72) 45 137 NA
Tunisia (1 study) NR 0.77 (0.22–2.77) 12 50 NA
Turkey (1 study) NR 2.63 (1.00–6.87) 24 67 NA
Brazil (1 study) NR 2.36 (0.27–20.76) 18 247 NA
All (11 studies) 1.30 (1.06, 1.59) 534 3096 0.0
Hom MT (AA) vs.
hom wt (GG)
China (3 studies) 1 study, 100% Chinese;
2 studies, NR
1.63 (0.66–4.00) 165 1356 58.1
Taiwan (2 studies) NR 1.52 (0.68–3.40) 74 250 0.0
South Korea (1 study) NR 5.26 (1.61–17.26) 39 107 NA
Indonesia (1 study) 100% Indonesian 3.29 (1.34–8.08) 29 102 NA
India (1 study) NR 0.64 (0.22–1.88) 25 100 NA
Tunisia (1 study) NR 3.71 (0.44–31.26) 9 28 NA
Turkey (1 study) NR 9.11 (1.91–43.46) 15 44 NA
Brazil (1 study) NR 1.25 (0.07–23.62) 17 246 NA
All (11 studies) 2.05 (1.24–3.40) 373 2233 47.7
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analyses stratified by the country in which the study
was conducted as a proxy variable for ethnicity. It is
clear that this approach is not ideal as the population
of any given country is often ethnically diverse.
However, stratifying by country was deemed the most
suitable approach in the absence of definitive
information on ethnicity.
An additional challenge was identifying distinct
patient cohorts from the included articles. If multiple
articles report data for the same patient cohort, data
for this patient cohort must only be included in meta-
analysis once, otherwise a unit-of-analysis error
occurs.18 We found that it was often not possible to
determine from the articles alone whether the patient
cohorts were identical. We contacted several study
authors for clarification. For two articles,51,68 we did
not receive a response and, consequently, data from
the older article68 were excluded from a meta-
analysis to which both articles contributed data. If
the two articles reported data for two distinct
cohorts, then information would have been lost by
excluding one article. Furthermore, there may have
been cases of multiple articles reporting outcomes for
the same cohorts that we did not identify; if this was
the case, some patients may have been double-
counted in the meta-analyses.
There was considerable variability in the defini-
tions of hepatotoxicity in the included studies, which
introduced heterogeneity into the meta-analyses.
Jorgensen et al.71 and Contopoulos-Ioannidis et
al.72 made similar observations about the variability
of definitions of outcomes across pharmacogenetics
studies. If outcome definitions were more consistent
between pharmacogenetic studies, the amount of
heterogeneity observed in meta-analyses would have
been reduced.
Finally, an important limitation of the systematic










803A-G (rs1208) Het (AG) vs. hom
wt (AA)
China (1 study) NR 1.63 (0.45–5.94) 101 107 NA
Taiwan (1 study) NR 1.36 (0.14–13.30) 70 285 NA
Indonesia (1 study) 100% Indonesian 1.15 (0.55–2.41) 49 187 NA
Brazil (1 study) NR 0.82 (0.27–2.52) 13 219 NA
All (4 studies) 1.14 (0.67–1.96) 233 798 0.0
Hom MT (GG) vs.
hom wt (AA)
China (1 study) NR Data excluded†
Taiwan (1 study) NR Data excluded†
Indonesia (1 study) 100% Indonesian 0.99 (0.11–9.09) 38 150 NA
Brazil (1 study) NR 2.32 (0.69–7.78) 12 140 NA
All (2 studies) 1.90 (0.66–5.52) 50 290 0.0%
857G-A
(rs1799931)
Het (GA) vs. hom
wt (GG)
China (3 studies) 1 study, 100% Chinese;
2 studies, NR
1.28 (0.74–2.22) 254 2069 61.5
Taiwan (2 studies) NR 1.13 (0.70–1.82) 103 368 0.0
South Korea (1 study) NR 1.11 (0.56–2.20) 65 150 NA
Indonesia (1 study) 100% Indonesian 1.41 (0.72–2.75) 49 190 NA
Tunisia (1 study) NR 0.70 (0.03–15.34) 14 52 NA
Turkey (1 study) NR 3.39 (0.84–13.67) 29 69 NA
Brazil (1 study) NR 2.19 (0.73–6.55) 17 250 NA
All (10 studies) 1.30 (1.03–1.64) 531 3148 0.9
Hom MT (AA) vs.
hom wt (GG)
China (3 studies) 1 study, 100% Chinese;
2 studies, NR
0.98 (0.38–2.51) 184 1677 0.0
Taiwan (2 studies) NR 5.05 (0.47–54.88) 82 268 74.2
South Korea (1 study) NR 1.18 (0.10–13.36) 50 118 NA
Indonesia (1 study) 100% Indonesian 4.31 (0.26–70.80) 33 139 NA
Tunisia (1 study) NR Data excluded*
Turkey (1 study) NR 2.71 (0.16–45.03) 25 66 NA
Brazil (1 study) NR 8.75 (0.74–103.44) 13 212 NA
All (9 studies) 1.99 (1.02–3.91) 387 2480 11.3
rs1495741 Het (AG) vs. hom
wt (AA)
Taiwan (1 study) NR 0.19 (0.07–0.52) 19 249 NA
Hom MT (GG) vs.
hom wt (AA)
Taiwan (1 study) NR 0.07 (0.01–0.56) 14 152 NA
rs4646244 Het (TA) vs. hom
wt (TT)
South Korea (1 study) NR 2.03 (1.09–3.78) 57 152 NA
Hom MT (AA) vs.
hom wt (TT)
South Korea (1 study) NR 4.06 (1.36–12.13) 37 110 NA
Rs4646267 Het (AG) vs. hom
wt (AA)
South Korea (1 study) NR 0.50 (0.25–0.98) 52 127 NA
Hom MT (GG) vs.
hom wt (AA)
South Korea (1 study) NR 0.63 (0.27–1.45) 35 66 NA
* Due to zero patients in one of the genotype groups.
† Data from two of the three Chinese studies were excluded due to zero counts.
SNP ¼ single nucleotide polymorphism OR ¼ odds ratio; CI ¼ confidence interval; het ¼ heterozygous genotype; hom wt ¼ homozygous wild-type; NR ¼ not
reported; NA¼ not applicable; hom MT¼ homozygous mutant-type.
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in Africa. There is a great deal of NAT2 diversity
across Africa,73 where TB is endemic, but there has
been little mapping of pharmacogenomic polymor-
phisms in African populations. Only four studies
included in this review were conducted in Africa. The
vast majority of evidence included in this review is
therefore not representative of the global population
most affected by TB.
Recommendations for authors of pharmacogenetic
studies
We made several recommendations regarding the
reporting of future pharmacogenetic studies to
facilitate the conduct of high-quality systematic
reviews and meta-analyses, and thus improve the
power to detect genetic associations.
1 Report the number of patients in each genotype
group;
2 Report outcomes for each genotype group sepa-
rately (i.e., number of events for dichotomous
outcomes, and mean and standard deviation values
for continuous outcomes);
3 Report the rs number of each genotyped SNP;
4 Report the ethnicity of included patients;
5 If a study includes more than one ethnic group,
provide the summary data specified in 1) and 2) per
ethnic group;
6 Provide the reference to the published protocol;
7 Provide information on patient cohort overlap;
8 Report full details of all variants and outcomes
investigated, and of all analyses undertaken;
9 Consensus should be reached between experts in
specific areas of research on the definitions of
outcomes that are commonly reported in pharma-
cogenetic studies of a particular treatment.
We also recommend that articles adhere to the
criteria of the quality assessment tool20 as improve-
ment in the methodological quality of studies
included in meta-analyses would in turn improve
the strength of the evidence synthesised in meta-
analyses. Furthermore, we recommend that STREGA
reporting guidelines are referred to, which provide
guidance on the reporting of genetic association
studies in general.74
CONCLUSION
This review showed that slow/intermediate acetyla-
tors were significantly more likely to experience
hepatotoxicity than rapid acetylators. Therefore,
pharmacogenetic testing may be useful in clinical
practice in terms of risk stratification for ATDH
during treatment of TB. However, more studies are
needed to overcome the reported methodological
limitations and to assess if this strategy might be
feasible and cost-effective.
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MEDLINE (Ovid) and MEDLINE
In-Process (Ovid)
3 March 2016 3029
EMBASE (Ovid) 3 March 2016 4778
PubMed 3 March 2016 379
Web of science 3 March 2016 421
Biosis 3 March 2016 328
Table A.2 Search strategies
A) Database: Web of science and Biosis
Approximately
1 634 627
#10 OR #7 OR #6 OR #5 OR #4
Approximately
9 565






TITLE: ((((TB or Tuberculosis* or Antitubercul*))))
Approximately
219 324
TITLE: ((((gene* or genetic*) near/5 (mutat* or variant*))))
Approximately
1 388 831
TITLE: ((((SNP or Genotyp* or Phenotyp* or Allele* or Pharmacogenet* or Pharmacogenom* or Polymorph*))))
Approximately
38 430
TITLE: (((single* near/2 nucleotid* near/2 polymorph*)))
Approximately
45 745
TITLE: ((((genetic* or gene*) near/3 (suscept* or predisposit* or anticipat*))))
Approximately
47 961
TITLE: (((aminosalicylic acid or diarylquinoline* or ethambutol* or ethionamide* or isoniazid* or prothionamide*




TITLE: ((((Antitubercul* or tuberculos* or TB) Near/4 (agent* or drug* or antibiotic* or medicine* or medication*
or treatment*))))
B) Database: Medline
# m Searches Results
1 antitubercular agents/ or aminosalicylic acid/ or diarylquinolines/ or ethambutol/ or ethionamide/ or isoniazid/ or
prothionamide/ or pyrazinamide/ or thioacetazone/ or antibiotics, antitubercular/ or capreomycin/ or cycloserine/
or enviomycin/ or rifabutin/ or rifampin/ or viomycin/
73 943
2 ((Antitubercul* or tuberculos* or TB) adj4 (agent* or drug* or antibiotic* or medicine* or medication* or
treatment*)).tw.
29 293
3 (aminosalicylic acid or diarylquinoline* or ethambutol* or ethionamide* or isoniazid* or prothionamide* or
pyrazinamide* or thioacetazone* or capreomycin* or cycloserine* or enviomycin* or rifabutin* or rifampin* or
viomycin*).tw.
26 053
4 1 or 2 or 3 93 357
5 Polymorphism, Genetic/ 103 705
6 genetic predisposition to disease/ or anticipation, genetic/ 101 390
7 Pharmacogenetics/ 9 595
8 Genetic Association Studies/ 14 210
9 ((Genetic or gene*) adj2 associat* adj2 (studies or study or analys*)).tw. 4 883
10 ((genetic* or gene*) adj3 (suscept* or predisposit* or anticipat*)).tw. 40 247
11 Polymorphism, Single Nucleotide/ 77 811
12 (single* adj2 nucleotid* adj2 polymorph*).tw. 46 260
13 (SNP or Genotyp* or Phenotyp* or Allele* or Pharmacogenet* or Pharmacogenom* or Polymorph*).tw. 774 469
14 ((gene* or genetic*) adj5 (mutat* or variant*)).tw. 182 197
15 Genotype/ or Phenotype/ or Alleles/ 381 555
16 or/5-15 1 035 512
17 exp Tuberculosis/ 175 110
18 (TB or Tuberculosis*).tw. 153 175
19 Antitubercul*.tw. 11 635
20 or/17-19 213 138
21 4 and 16 and 20 2 846
22 animal/ not human/ 4 159 388
23 21 not 22 2 730
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Table A.2 (continued)
C) Database: Embase
# m Searches Results
1 antitubercular agents/ or aminosalicylic acid/ or diarylquinolines/ or ethambutol/ or ethionamide/ or isoniazid/ or
prothionamide/ or pyrazinamide/ or thioacetazone/ or antibiotics, antitubercular/ or capreomycin/ or cycloserine/
or enviomycin/ or rifabutin/ or rifampin/ or viomycin/
151 901
2 ((Antitubercul* or tuberculos* or TB) adj4 (agent* or drug* or antibiotic* or medicine* or medication* or
treatment*)).tw.
40 664
3 (aminosalicylic acid or diarylquinoline* or ethambutol* or ethionamide* or isoniazid* or prothionamide* or
pyrazinamide* or thioacetazone* or capreomycin* or cycloserine* or enviomycin* or rifabutin* or rifampin* or
viomycin*).tw.
34 743
4 1 or 2 or 3 172 588
5 Polymorphism, Genetic/ 102 257
6 genetic predisposition to disease/ or anticipation, genetic/ 97 585
7 Pharmacogenetics/ 17 431
8 Genetic Association Studies/ 876
9 ((Genetic or gene*) adj2 associat* adj2 (studies or study or analys*)).tw. 7 890
10 ((genetic* or gene*) adj3 (suscept* or predisposit* or anticipat*)).tw. 61 544
11 Polymorphism, Single Nucleotide/ 98 303
12 (single* adj2 nucleotid* adj2 polymorph*).tw. 75 841
13 (SNP or Genotyp* or Phenotyp* or Allele* or Pharmacogenet* or Pharmacogenom* or Polymorph*).tw. 1 171 894
14 ((gene* or genetic*) adj5 (mutat* or variant*)).tw. 294 715
15 Genotype/ or Phenotype/ or Alleles/ 777 386
16 or/5-15 1 548 879
17 exp Tuberculosis/ 197 008
18 (TB or Tuberculosis*).tw. 187 590
19 Antitubercul*.tw. 16 330
20 or/17-19 253 048
21 4 and 16 and 20 5 380
22 animal/ not human/ 1 357 016
23 21 not 22 5 360
24 limit 23 to em¼188300-201608 4 778
D) Database: PubMed
#1 Search (((Antitubercul* or tuberculos* or TB))) AND ((agent* or drug* or antibiotic* or medicine* or medication*
or treatment*))
124 242
#2 Search ((aminosalicylic acid or diarylquinoline* or ethambutol* or ethionamide* or isoniazid* or prothionamide*
or pyrazinamide* or thioacetazone* or capreomycin* or cycloserine* or enviomycin* or rifabutin* or rifampin*
or viomycin*))
49 591
#3 Search (#1 or #2) 151 329
#4 Search ((((Genetic or gene*) near/2 near/2 ))) AND associat*) AND ((studies or study or analys*)) 3 922
#5 Search (((genetic* or gene*))) AND ((suscept* or predisposit* or anticipat*)) 235 548
#6 Search ((single*) AND nucleotid*) AND polymorph* 98 071
#7 Search ((SNP or Genotyp* or Phenotyp* or Allele* or Pharmacogenet* or Pharmacogenom* or Polymorph*)) 997 538
#8 Search (((gene* or genetic*))) AND ((mutat* or variant*)) 743 819
#9 Search (#4 or #5 or #6 or #7 or #8) 1 553 428
#10 Search (((((TB or Tuberculosis* or Antitubercul*))))) 251 923
#11 Search (#3 and #9 and #10) 7 671
#12 Search (‘‘2015/08/01"[Date - Entrez] : ‘‘3000"[Date - Entrez]) 658 085
#13 Search (#11 and #12) 379
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Table A.4 Definitions of hepatotoxicity in the included studies
Author, year Outcome and definition
An, 2012 ATDH was defined as an increase of .23 ULN range in ALT or conjugated bilirubin levels or a concurrent
increase in AST levels, according to the criteria of DILI developed at an international consensus meeting1
Azuma, 2013 INH-DILI was assessed according to the diagnostic criteria of the Manual for Serious Side Effects of Drug-
induced Liver Injury from the Ministry of Health, Labor and Welfare of Japan.2,3 In brief, hepatocellular
injury was defined as a .2-fold increase in the ULN concentration of ALT alone or a serum ALT ratio/
ALP ratio . 5, where the ALT ratio ¼ ALT value/ULN of ALT, and ALP ratio ¼ ALP value/ULN of ALP.
Cholestatic injury was defined as an increase above 2-fold of the ULN range of ALP or a serum ALT
ratio/ALP ratio , 2. Mixed injury was defined as a serum ALT ratio/ALP ratio of between 2 and 5.
Causality assessments showed a relationship to the INH administration if the total score was more than
grade 3, i.e. ‘possible’
Bose, 2011; Yimer 2011 ATDH (Bose 2011)/DILI (Yimer 2011) in patients was defined according to the international consensus
criteria.1 Liver biochemical parameters .2 times the ULN value was considered as hepatotoxicity
C¸etintas, 2008 Drug-induced hepatitis criteria were defined as follows: 1) an increase in AST and ALT levels of .3-fold
above normal or .5-fold above starting level or, 2) a greater than normal increase in ALT and AST levels
together with hepatitis symptoms or, 3) a high bilirubin level
Chamorro, 2013 Hepatotoxicity was defined as when serum transaminase concentrations were at least 33 ULN (normal
values: AST 0–32 IU/l and ALT 0–31 IU/l) with report of jaundice (bilirubin normal values: 0–1 mg/dl) and/
or hepatitis symptoms (nausea, vomiting, abdominal pain), or .53 ULN with or without symptoms
Chang, 2012 ATDH was ‘defined according to the classification of the CIOMS’.1 No further information was provided
Cho, 2007; Jung, 2015;
Lee, 2010
ATDH was designated as an increase in serum ALT level . 23 ULN after anti-tuberculosis treatment,
according to the criteria for DILI developed by the international consensus meeting1
Feng, 2014; Teixeira, 2011 Anti-tuberculosis drug-induced hepatitis (Teixeira 2011)/anti-tuberculosis drug-induced hepatic injury (Feng
2014): an increase in serum transaminase values to .33 ULN values (40 IU/l ALT in Feng) and symptoms
compatible with hepatitis
Fredj, 2016 The causality of drug-induced hepatotoxicity was determined according to the report of an international
consensus meeting.1 These criteria include 1) an increase of liver transaminases levels of .2 times above
the normal value (,40 IU/l) for AST and ALT, 2) an improvement of this pattern after the drug
withdrawal, and 3) the absence of alternative causes of this disorder
Gupta, 2013
(GI: GUPTA)
Increase in ALT . 23 ULN or a combined increase in AST and bilirubin levels, provided one of them is .23
ULN, was defined as ATDH according to the international consensus meeting1
Higuchi, 2007 DIH was defined according to the criteria of the international consensus meeting,1 i.e., development of a
72-fold increase in serum ALT level above the ULN range: N (642 IU/l), or a combined increase of. 2 N
in serum AST (N 6 33 IU/l) and total bilirubin (N 6 1.5 mg/dl)
Ho, 2013 The criteria for the diagnosis of hepatotoxicity was an elevation in liver function tests, AST and/or ALTof.5
3 ULN; or AST and/or ALT of .33 ULN in the presence of symptoms such as nausea, vomiting, poor
appetite, abdominal pain or jaundice; or AST and/or ALT of .33 ULN in the presence of total bilirubin of
.23 ULN
Huang, 2003 (GI: HUANG) Anti-tuberculosis drug-induced hepatitis was diagnosed as 1) an increase in serum ALT level . 23 ULN
during treatment, according to the criteria established by the international consensus meeting;1 2)
negative serum HBV surface antigen, IgM antibody to HAV, and antibody to HCV when ALT or AST is
elevated; 3) without any other major hepatic or systemic diseases that may induce elevation of liver
biochemical tests, such as alcoholic liver disease, autoimmune hepatitis, congestive heart failure, hypoxia,
and bacteremia; and 4) a causality assessment score . 5 (when classified as ‘probable’ or ‘highly
probable’ drug-induced hepatitis), as derived from the international consensus meeting1
Khalili, 2011 Hepatotoxicity was defined as 1) increased levels of liver transaminases . 3 times above the normal value
(,40 U/l for AST and ALT) with any other clinical signs and symptoms; or 2) elevation of transaminases.
53 ULN, if patients had no symptoms. For evaluation of causality, The Roussel Uclaf Causality
Assessment Method scoring system was used2
Kim, 2009 (GI: KIM) Anti-tuberculosis drug-induced hepatitis was defined as an elevation in the serum levels of ALT . 23 ULN
(640 U/ml) during treatment and normalisation of these values after cessation of medication according
to the criteria from the international consensus meeting1
Leiro-Fernandez, 2011 ATDH was defined as an increase in serum transaminase (either ASTor ALT) to values. 33 ULN (i.e.,.120
IU/l) at any time during the treatment period
Lv, 2012 ATDH was designated as an increase of .23 ULN value in ALT or a combined increase in AST and total
bilirubin provided one of them is .23 ULN. In this study, the ULN of ALT, AST and total bilirubin were
respectively 40 U/l, 40 U/l and 19 lmol/l
Causality assessment result was highly probable, probable or possible based on the CIOMS scale1
Mahmoud, 2012 DIH was diagnosed as 1) an increase in serum ALT level greater than twice the ULN during the treatment,
according to the criteria established by the international consensus meeting;1 2) negative serum HBV
surface antigen, IgM antibody to HAV, and antibody to HCV when ALT or AST was elevated; 3) without
any other major hepatic or systemic diseases that may induce elevation of liver biochemical tests, such as
alcoholic liver disease, autoimmune hepatitis, congestive heart failure, hypoxia, and bacteremia; when
the French imputability score4 was classified as ‘probable’ or ‘likely’ or ‘certain’
Ng, 2014 All cases of DILI met at least one of the following biochemical criteria for enrolment into this study: 1) ALT.
53 ULN, 2) ALP . 23 ULN, or 3) ALT . 33 ULN and bilirubin . 23 ULN
Ohno, 2000 Hepatotoxicity was estimated as follows: AST and/or ALT . 1.53 ULN and 23 before administration
Possuelo, 2008 (GI:
POSSUELO)
Criteria for the diagnosis of hepatotoxicity was an elevation in liver function tests, AST and/or ALT of .33
ULN (reference: respectively 40 and 65 U/l) and/or in total bilirubin up to .2.0 mg/dl in the presence of
such gastrointestinal symptoms as anorexia, nausea, vomiting and/or jaundice, with a normalisation of
serum ALT level after discontinuation of the anti-tuberculosis drugs
Rana, 2014
(GI: RANA)
ATDH was defined according to international consensus criteria.1 Patients with a rise in serum AST or ALT
levels7 53 ULN, irrespective of symptoms and serum bilirubin levels, or patients with rise in serum AST
or ALT levels 7 23 ULN with hyperbilirubinaemia and an absence of serological evidence of infection
with hepatitis viruses (A, B, C and E) were considered as having ATDH
NAT2 and anti-tuberculosis drug-related toxicity i
Table A.4 (continued)
Author, year Outcome and definition
Santos, 2013
(GI: SANTOS)
Hepatotoxicity was defined as an increase in serum ALT level in excess of three times the ULN after INH
treatment
Shimizu, 2006 Hepatotoxicity was defined as an ALT and/or AST level more than twice the institutional ULN according to
the modified criteria of the international consensus meeting for drug-induced liver disorders.1 The ULN
for AST was 33 IU/l and that for ALT was 42 IU/l
Singla, 2014 International consensus criteria1 define ATDH as development of .23 ULN value of ALT and AST. The ULN
values used in this study were 35 U/l ALT and 40 U/l AST
Sotsuka, 2011 The severity of hepatotoxicity (hepatotoxicity A–D) was judged by the increase in either AST or ALT levels
from the ULN range (AST, 33 U/l; ALT, 42 U/l): hepatotoxicity A, above the upper limit and less than 2-fold
increase; hepatotoxicity B, 2- to 3-fold increase; hepatotoxicity C, 3- to 4-fold increase; hepatotoxicity D,
greater than 4-fold increase. Results for grades B–D of hepatotoxicity were used in this review as clinical
opinion was that the hepatotoxicity A patients would not have met the criteria for hepatotoxicity in many
of the other studies included in this review
Vuilleumier, 2006 Criteria for the diagnosis of INH-H comprised elevation in AST and/or ALT levels 4-fold above the upper
reference limit (168 UI/l) with or without symptoms. CDS were used to assess the likelihood of drug
involvement when INH-H was suspected.5 Based on the CDS, causality assessment of INH-H was then
categorised as definite (score . 17), probable (14–17), possible (10–13), unlikely (6–9) or excluded (,6).
INH-H with possible to probable scores were considered for statistical analysis; unlikely scores were still
considered when no other factor was identifiable
Wang, 2011
(GI: NTUH)
HATT was defined as increased serum AST and/or ALT . 1.5 times the baseline level. Results are presented
for drug-induced HATT and virus-induced HATT separately. In this review, we used the results for drug-
induced HATT. The diagnosis of INH- or RMP-induced HATT required a positive re-challenge test (at least
doubling of serum AST or ALT level and recurrence of clinical symptoms of hepatitis after re-challenge),
whereas PZA-induced HATT was diagnosed by exclusion
Wang, 2015
(GI: NTUH)
Hepatitis during anti-tuberculosis treatment was defined as increased serum AST and/or ALT . 33 ULN in
symptomatic patients, or .53 ULN in asymptomatic patients. The diagnosis of INH- or RMP-induced
hepatitis required a positive re-challenge test (at least doubling of serum AST or ALT levels and recurrence
of clinical symptoms of hepatitis after re-challenge), whereas PZA-induced hepatitis was diagnosed either
by a positive re-challenge test or by exclusion. Results are presented for overall drug-induced HATT and
INH-induced HATT separately. In this review, we used the results for overall drug-induced HATT as our
review focuses on hepatotoxicity induced by any anti-tuberculosis drug
Xiang, 2014 ATLI was defined as an ALT, AST or bilirubin value . 23 ULN. The ULN used in the study was 40 Ul for ALT,
40 U/l for AST, and 19 mmol/l for total bilirubin
Yamada, 2009 ATDH was defined as an increase in serum AST level . 23 ULN during 9 months of treatment with INH
according to the criteria of the international consensus meeting in Paris;1 normalisation of serum AST
level after discontinuation of INH; and a causality assessment score2 of .8, corresponding to the
category of highly probable hepatotoxicity
Yuliwulandari, 2016 ATLI: definition not reported
Zaverucha-do-Valle, 2014 Hepatotoxicity was defined as 23 ULN (ALT 42 IU/l) or at least a 2-fold increase in ALT initial levels in
patients with a baseline ALT of .84 IU/l during the treatment period
ULN¼ upper limit of normal; ALT¼alanine aminotransferase; AST¼aspartate aminotransferase; DILI¼ drug-induced liver injury; INH¼ isoniazid; ALP¼ alkaline
phosphatase; ATDH¼anti-tuberculosis drug-induced hepatotoxicity; IU¼ international unit; DIH¼drug-induced hepatotoxicity; CIOMS¼Council for International
Organizations of Medical Sciences; GI¼group identifier; HBV¼hepatitis B virus; IgM¼ immunoglobulin M; HAV¼hepatitis A virus; HCV¼hepatitis C virus; CDS¼
Clinical Diagnostic Scale; INH-H¼ INH-induced hepatitis; RMP¼ rifampicin; PZA¼pyrazinamide; HATT¼hepatitis during anti-tuberculosis treatment; ATLI¼ anti-
tuberculosis drug-induced liver injury;
Table A.5 Definitions of other toxicity outcomes in the included studies
Outcome Author, year Outcome definition
Peripheral neuropathy Azuma, 2013 NR
Dhoro, 2013 NR
Adverse DIH outcome Bose, 2011 ‘16 [patients] showed an adverse outcome of anti-tuberculosis treatment
hepatotoxicity with icterus, severe nausea and vomiting’. No further details
reported
ADRs Costa, 2012 The presence of at least one of the following symptoms during the follow-up
period: gastric, joint, neuromuscular or skin reactions; and hepatotoxicity (in
accordance with the criteria of drug-induced liver injuries developed by the
international consensus meeting)6
Skin rash Higuchi, 2007 NR
Eosinophilia Higuchi, 2007 The presence of .450 eosinophils/ml
ATD-induced MPE Kim, 2011 (GI: KIM) The development of MPE after receiving first-line ATD and the disappearance
of MPE after discontinuing ATD due to MPE
Gastrointestinal ADRs Possuelo, 2008 (GI: POSSUELO) Anorexia, nausea, vomiting and/or abdominal pain
NR¼ not reported; DIH¼ drug-induced hepatotoxicity; ADR¼ adverse drug reaction; ATD¼ anti-tuberculosis drug; MPE¼macropapular eruption; GI¼ group
identifier.
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Figure A.1 Sensitivity analysis 1: pairwise comparisons of slow vs. rapid acetylator status for the outcome of hepatotoxicity.
* Conducted in LTBI populations. † Caucasian (n¼ 38, 43%), Hispanic (n¼ 8, 9%), African (n¼ 22, 25%), South American (n¼ 15,
17%), Asian (n¼ 5, 6%), Middle Eastern (n¼ 1, 1%). ‡ Asian (n¼ 72, 42%), Caucasian (n¼ 49, 29%), South Asian (n¼ 22, 13%),
Hispanic (n¼7, 4%), Middle Eastern (n¼8, 5%), First nations (n¼5, 3%), Other/mixed/unknown: (n¼7, 4%). OR¼odds ratio; CI¼
confidence interval; GI¼ group identifier; LTBI¼ latent tuberculous infection.
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Figure A.2 Sensitivity analysis 1: Intermediate vs. rapid acetylator status for the outcome of hepatotoxicity. * Conducted in LTBI
populations. † Caucasian (n¼ 38, 43%), Hispanic (n¼ 8, 9%), African (n¼ 22, 25%), South American (n¼ 15, 17%), Asian (n¼ 5,
6%), Middle Eastern (n¼1, 1%). ‡ Asian (n¼72, 42%), Caucasian (n¼49, 29%), South Asian (n¼22, 13%), Hispanic (n¼7, 4%),
Middle Eastern (n¼8, 5%), First nations (n¼5, 3%), Other/mixed/unknown: (n¼7, 4%). OR¼odds ratio; CI¼confidence interval; GI
¼ group identifier; LTBI¼ latent tuberculous infection.
iv The International Journal of Tuberculosis and Lung Disease
Figure A.3 Sensitivity analysis 2: Slow vs. rapid/intermediate acetylator status for the outcome of hepatotoxicity. * Conducted in
LTBI populations. † Caucasian (n¼38, 43%), Hispanic (n¼8, 9%), African (n¼22, 25%), South American (n¼15, 17%), Asian (n¼5,
6%), Middle Eastern (n¼ 1, 1%). ‡Asian (n¼ 72, 42%), Caucasian (n¼49, 29%), South Asian (n¼ 22, 13%), Hispanic (n¼ 7, 4%),
Middle Eastern (n¼8, 5%), First nations (n¼5, 3%), Other/mixed/unknown: (n¼7, 4%). OR¼odds ratio; CI¼confidence interval; GI
¼ group identifier; LTBI¼ latent tuberculous infection.
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Figure A.4 Funnel plot for the primary analysis.
vi The International Journal of Tuberculosis and Lung Disease
Figure A.5 NAT2 SNPs and hepatotoxicity meta-analyses: heterozygous genotype (CT) vs. homozygous wt genotype (CC) for the
outcome of hepatotoxicity. A) Heterozygous genotype (CT) vs. homozygous wt genotype (CC) for the outcome of hepatotoxicity. B)
Homozygous mutant genotype (TT) vs. homozygous wt genotype (CC) for the outcome of hepatotoxicity. C) Heterozygous genotype
(TC) vs. homozygous wt genotype (TT) for the outcome of hepatotoxicity. D) Homozygous mutant genotype (CC) vs. homozygous wt
genotype (TT) for the outcome of hepatotoxicity. E) Heterozygous genotype (CT) vs. homozygous wt genotype (CC) for the outcome
of hepatotoxicity. F) Homozygous mutant genotype (TT) vs. homozygous wt genotype (CC) for the outcome of hepatotoxicity. G)
Heterozygous genotype (GA) vs. homozygous wt genotype (GG) for the outcome of hepatotoxicity.H) Homozygous mutant genotype
(AA) vs. homozygous wt genotype (GG) for the outcome of hepatotoxicity. I) Heterozygous genotype (GA) vs. homozygous wt
genotype (AA) for the outcome of hepatotoxicity. J) Homozygous mutant genotype (GG) vs. homozygous wt genotype (AA) for the
outcome of hepatotoxicity. K) Heterozygous genotype (GA) vs. homozygous wt genotype (GG) for the outcome of hepatotoxicity. L)
Homozygous mutant genotype (AA) vs. homozygous wt genotype (GG) for the outcome of hepatotoxicity. OR ¼ odds ratio; CI ¼
confidence interval; GI¼group identifier; wt¼wild type; NAT2¼N-acetyltransferase 2; SNP¼ single-nucleotide polymorphism; mt¼
mutation.
NAT2 and anti-tuberculosis drug-related toxicity vii
Figure A.5 (continued)
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R E´ S U M E´
C A D R E : Les patients tuberculeux recevant un
traitement antituberculeux peuvent souffrir d’effets
secondaires graves aux me´dicaments, comme la
toxicite´ he´patique. Les variants ge´ne´tique du ge`ne
NAT2 pourraient accroıˆtre le risque de ces effets
secondaires de la toxicite´ des me´dicaments.
O B J E C T I F : Fournir une e´valuation comple`te des
e´le´ments en faveur de l’association entre les variants
ge´ne´tiques de NAT2 et la toxicite´ des antituberculeux.
M E´ THODE : Ceci est une revue syste´matique et me´ta-
analyse. Nous avons recherche´ des e´tudes sur Medline,
EMBASE, BIOSIS et le Web of Science. Nous avons
inclus des donne´es de 41 articles (39 cohortes distinctes
de patients). Nous avons groupe´ l’estimation des effets
pour chaque ge´notype et pour chaque re´sultat avec une
me´ta-analyse stratifie´e par pays. Nous avons re´alise´ une
e´valuation qualitative de la qualite´ des e´tudes incluses.
R E´ S U LTAT S : La qualite´ des e´tudes incluses a e´te´
variable, avec de nombreux sujets de pre´occupation.
Les ace´tyleurs lents/interme´diaires de NAT2 ont e´te´
statistiquement significativement plus susceptibles de
souffrir d’une he´patotoxicite´ que les ace´tyleurs rapides
(OR 1,59 ; IC95% 1,26–2,01). Aucune he´te´roge´ne´ite´ n’a
e´te´ de´tecte´e dans l’ensemble de l’analyse regroupe´e (I2¼
0%). Le statut d’ace´tyleur de NAT2 est significativement
associe´ a` la probabilite´ de toxicite´ he´patique lie´e aux
me´dicaments antituberculeux.
CONC LU S I ON : Nous avons rencontre´ de nombreux
de´fis dans la re´alisation d’une synthe`se solide des
donne´es des e´tudes pharmacoge´ne´tiques et nous
pre´sentons des recommandations pour les futurs
rapports des e´tudes pharmacoge´ne´tiques afin de
permettre de re´aliser des revues syste´matiques et des
me´ta-analyses de bonne qualite´.
R E S UM E N
MARCO DE R E F E R ENC I A: Los pacientes que reciben
tratamiento antituberculoso pueden presentar
reacciones adversas graves a los medicamentos, por
ejemplo la hepatotoxicidad. Los polimorfismos
gene´ticos de NAT2 pueden aumentar el riesgo de
aparicio´n de este tipo de reacciones adversas.
OB J E T I VO: Aportar una evaluacio´n exhaustiva de la
base de datos probatorios sobre la asociacio´n entre los
polimorfismos gene´ticos de NAT2 y la toxicidad
atribuida a los medicamentos antituberculosos.
M E´ T O D O: Esta es una revisio´n sistema´tica con
metana´lisis. Se buscaron artı´culos en las bases de datos
Medline, EMBASE, BIOSIS y Web of Science. Se
incluyeron datos de 41 artı´culos (39 cohortes de
pacientes diferentes). Se combinaron las estimaciones
del efecto para cada genotipo con cada resultado,
mediante un metana´lisis estratificado por paı´ses. Se
realizo´ una evaluacio´n cualitativa de los estudios
incluidos.
R E SU LTADOS: La calidad de los estudios incluidos fue
variable, con muchos aspectos que son fuente de
preocupacio´n. La probabilidad de hepatotoxicidad en
los acetiladores lentos e intermedios de NAT2 fue
significativamente mayor que en los acetiladores
ra´pidos (OR 1,59; IC95% 1,26–2,01). No se detecto´
heterogeneidad en el ana´lisis global combinado (I2 ¼
0%). El fenotipo acetilador de NAT2 se asocio´ de
manera significativa con la probabilidad de aparicio´n de
hepatotoxicidad debida a los medicamentos
antituberculosos.
CONC LU S I O´ N: Se encontraron dificultades importantes
al tratar de realizar una sı´ntesis so´lida de los datos de
estudios farmacogene´ticos, por lo cual se proponen
recomendaciones sobre la comunicacio´n de los
resultados de futuros estudios farmacogene´ticos, que
faciliten la realizacio´n de revisiones sistema´ticas y
metana´lisis de gran calidad.
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